Titan Pharmaceutics---Strong Buy---- - 500 Beiträge pro Seite

[cineman]

hi leute,

Kann euch hier eine sehr interessante Biotech Aktie vorstellen.
Es handelt sich um die des Pharma Konzerns TITAN Pharamceutics.

Habe mich hier wie auch in anderen Boards umgehorcht und mußte feststellen das diese Aktie eine Perle ist.
Ich habe auf einer Web-seite:

http://www1.zacks.com/cgi-bin/JMFR/FreeReport?ref=INSIDEWALL…

gelesen, das sie von 5 Analysten zu STRONG BUY eingestuft wurde.

viel Spaß mit dieser Aktie......(ich habe mich schon ein genügend eingedeckt :-) )

cineman

[Krisu1]

Hallo cineman,

was macht oder entwickelt Titan Pharmaceutis eigentlich?
Welche WKN hat sie, denn bei comdirect habe ich nichts gefunden!

Krisu1

[cineman]

hi krisu1,

sieh dir einfach ihre Homepage an:

http://www.titanlabs.com/

WKN: 914404

Sie wird in Frankfurt und Berlin gehandelt.

viel spaß mit dieser Aktie, sie wird mit ziemlicher Sicherheit ihren Weg machen

cineman

[Krisu1]

Hall cineman

Ich habe mich in der Zwischenzeit etwas über Titan Pharmaceuticals informiert. Hört sich wirklich alles sehr vielversprechend an.

Titan entwickelt das Medikament Zomaril zur Bekämpfung von Schizophrenie und Spheramine zur Behandlung der Parkinson-Krankheit.
Zomaril ist derzeit in der Phase III der klinischen Testung durch ihren Kooperationspartner, die Novasis Pharma AG.
Titan hat auch schon beachtliche Erfolge in der Krebsforschung erzielt.

Der Wert ist aber meiner Meinung nach schon ziemlich gut gelaufen. Zu welchem Kurs bist Du eingestiegen?
Trotzdem sagen alle Analysten Strong Buy und ich glaube, ich werde mich mal mit einer kleinen Position eindecken.
Kannst Du mir noch mehr zu diesem Wert sagen?

Krisu1

[cineman]

hi leute

hier einige News....bildet selbst eure Meinung !


Titan Reports Second Quarter 2000 Financial Results

Business Editors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 15, 2000-- Titan Pharmaceuticals, Inc. (AMEX: TTP) today announced financial results for the second quarter and first six months of 2000.

Revenues for the second quarter and for the first six months of 2000 were approximately $281,000 and $616,000, respectively. Revenues increased compared to the same period last year when revenues were approximately $47,000 for the first six months of 1999. Revenues consisted principally of contract revenue from Titan`s corporate partnership with Schering AG for development of Spheramine(TM), Titan`s novel therapy for Parkinson`s disease.

Interest income for the second quarter and first six months of 2000 was approximately $1.3 million and $2.2 million respectively, an increase from $147,000 and $289,000, respectively for the second quarter and first six months of 1999. This increase is a result of the Company`s significantly greater cash and cash equivalents position compared with 1999. At June 30, 2000, the Company had a cash position of approximately $82.5 million.

Titan`s net loss for the second quarter and first six months of 2000 was approximately $2.4 million or $0.09 per share and $6.1 million or $0.24 per share, respectively, representing a decrease in net loss compared to the same periods last year of approximately $3.1 million or $0.20 per share and $5.9 million or $0.39 per share, respectively.

General and administrative expenses for the second quarter and first six months of 2000 were approximately $704,000 and $1.6 million, respectively. For the second quarter and first six months of 1999, Titan`s general and administrative expenses were approximately $529,000 and $1.3 million, respectively. The increase in general and administrative expenses from 1999 to 2000 was principally due to expenses during the first quarter 2000 for leasehold improvements and other expenses.

Research and development expenses in the second quarter and first six months of 2000 were approximately $3.3 million and $7.3 million, respectively. Research and development expenses in the second quarter and first six months of 1999 were approximately $2.7 million and $4.8 million, respectively. The increase in research and development expense was a result of the expansion of Titan`s randomized, placebo-controlled Phase III clinical study of CeaVac(R) in Dukes` D colorectal cancer, and increased manufacturing and development activity for CeaVac, and for Titan`s other anti-cancer therapeutic monoclonal antibodies, TriAb(R) and TriGem(TM), to support the initiation of three additional clinical efficacy studies later this year. These additional studies will be directed and managed by three government sponsored cooperative groups and be supported by the Cancer Treatment and Evaluation Program of the National Cancer Institute (NCI).

Commenting on these results, Dr. Louis R. Bucalo, Chairman, President and CEO of Titan stated, "Our financial results for the second quarter and first half of this year were in line with expectations and demonstrate Titan`s ability to significantly advance our product portfolio in clinical testing in an efficient and cost-effective manner. With the recent acquisition of gallium maltolate, an oral agent for the potential treatment of cancer, cancer related conditions, and HIV, Titan currently has seven novel therapeutics in human testing, with two additional products in preclinical development that are targeted for initial clinical testing next year. Our core development programs are advancing very well, with substantial progress this past quarter in our cancer immunotherapy, Spheramine, and Zomaril clinical programs."

Continuing, Dr. Bucalo stated, "Titan`s Phase III clinical study of CeaVac in Dukes` D colorectal cancer is progressing on target, with approximately 500 patients enrolled to date. In addition, several government sponsored, cooperative group clinical trials, including two Phase III studies, are in preparation for testing of Titan`s monoclonal antibody based cancer therapies in a number of additional cancer targets. Our Phase I/II clinical study of Spheramine for treatment of Parkinson`s disease is progressing well, and the Zomaril Phase III program conducted by Novartis continues to advance well and on schedule. We look forward to the opportunity of further important progress in the near future."

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company`s development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company`s drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company`s drug candidates that could slow or prevent product markets, the uncertainty of patent protection for the Company`s intellectual property or trade secrets and the Company`s ability to obtain additional financing if necessary. Such statements are based on management`s current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. -0-


TITAN PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amount)

Three Months Six Months
Ended June 30, Ended June 30,
2000 1999 2000 1999
(unaudited)

Contract and
grant revenue $ 281 $ - $ 616 $ 47

Operating expenses:

Research and
development 3,266 2,724 7,311 4,810

Acquired in-process
research and
development - - - 136

General and
administrative 704 529 1,561 1,316

Total operating
expenses 3,970 3,253 8,872 6,262

Loss from operations (3,689) (3,253) (8,256) (6,215)

Interest and other
income, net 1,266 147 2,185 289

Net loss $ (2,423) $ (3,106) $ (6,071) $ (5,926)

Basic and diluted net
loss per share $ (0.09) $ (0.20) $ (0.24) $ (0.39)

Shares used in
computing basic and
diluted net loss
per share 25,769 15,385 24,821 15,036



CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, December 31,
2000 1999
(unaudited) (Note A)


Assets

Cash, cash equivalents,
and short term investments $ 82,515 $ 46,454

Grants receivable - 150

Prepaid expenses and
other current assets 467 327

Total current assets 82,982 46,931

Furniture and equipment, net 515 415

Other assets 16 16

$ 83,513 $ 47,362

Liabilities and
Stockholders` Equity

Current liabilities $ 1,579 $ 1,819

Minority interest -
Series B preferred